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Abstract Malignant progression in gliomas is correlated with
increased migratory capacity which involves metalloproteolytic
activity. Here, we report that ectopic expression of BCL-2 in two
malignant glioma sublines markedly promoted glioma cell
migration from spheroids and invasion into Matrigel-coated
membranes. Invasion of fetal rat-brain aggregates was enhanced
by BCL-2. Zymography revealed activation of matrix metallo-
proteinase-2 (MMP-2) in BCL-2-expressing cells. BCL-2
expressing cells showed an increase in MMP-2/-3/-12 (LN-18),
and MMP-9/-12 and cell surface urokinase-type plasminogen
activator (u-PA) (LN-229) mRNA and a reduction in tissue
inhibitors of metalloproteinases (TIMP)-2 mRNA (LN-229).
Taken together, we propose a novel function for BCL-2 in the
malignant phenotype of glioma cells, that is, to enhance
migration and invasion by altering the expression of a set of
metalloproteinases and their inhibitors.
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1. Introduction
Malignant gliomas are characterized pathologically by an
extensive in¢ltration of the surrounding normal brain tissue.
Therefore, a better understanding of migratory and invasive
mechanisms of glioma cells may result in new therapeutic
approaches. Glioma invasion is thought to rely on the mod-
i¢cation of cell adhesion and proteolysis of extracellular ma-
trix components [1]. Activation of matrix metalloproteinases
(MMP-2/-9) is observed in high grade gliomas but not in low
grade gliomas. The ability of glioma cells to spread on myelin
depends on metalloproteolytic activity [2]. Recently, the tu-
mor suppressor gene p16/CDKN2 has been shown to down-
regulate MMP-2 expression in the human SNB19 glioma cell
line, resulting in the suppression of glioma invasion in vitro
[3]. Also, cells transfected with an antisense cell surface uro-
kinase-type plasminogen activator (u-PA) receptor revealed
decreased invasiveness [4]. Successful migration and invasion
of glioma cells requires their resistance to the endogenous
death program of apoptosis once the cell has detached from
the primary tumor tissue. BCL-2, the prototype inhibitor of
apoptosis, has been suggested to regulate cell-cell interactions
[5], including integrin-dependent regulation of cell adhesion
via r-ras [6]. Vice versa, BCL-2 expression is up-regulated
by K5L1 integrins, preventing apoptosis when cells are de-
tached from matrix, or down-regulated in endothelial cells
by an KvL3 integrin antibody, with subsequent induction of
apoptosis [7]. Further, BCL-2 promotes the metastatic poten-
tial of the human breast cancer cell line MCF7 in vivo and
migratory and invasive properties in vitro [8]. These observa-
tions prompted us to examine a possible link between BCL-2
and cell motility in human glioma cells. In the present study,
we show that ectopic expression of BCL-2 changes the expres-
sion patterns of metalloproteinases and their inhibitors to-
wards a more invasive phenotype. Further, BCL-2-expressing
cells show enhanced migration and invasion in Matrigel inva-
sion as well as in fetal rat brain confrontation assays.
2. Materials and methods
2.1. Cell lines and cell culture
LN-18 and LN-229 cells were kindly provided by Dr. N. de Tribo-
let (Lausanne, Switzerland). The cells were cultured in Dulbecco’s
modi¢ed Eagle’s medium (DMEM) supplemented with 10% fetal
calf serum (FCS), 1% penicillin/streptomycin, and 0.5% Geneticin
(Boehringer, Mannheim, Germany). The generation of glioma cell
sublines expressing the murine BCL-2 protein has been described
[9]. Immunodetection of BCL-2 was done using the mouse anti-Bcl-
2 polyclonal antibody (1:1000, Santa Cruz Biotechnology, Santa
Cruz, CA, USA) [10].
2.2. Assessment of viability and clonogenicity
Cell growth, generation times and survival were assessed by crystal
violet staining. Clonogenicity was assayed by suspending the cells in
2 ml medium/well of a six-well plate and counting the number of
macroscopically visible clones (s 0.15 mm in diameter) after 10^19
days. The number of cells invaded through Matrigel was determined
by the microculture tetrazolium (MTT) assay.
2.3. Matrigel invasion assay
Invasion of glioma cells in vitro was measured by the invasion of
cells through Matrigel-coated transwell inserts (Becton Dickinson,
Heidelberg, Germany) [11]. Brie£y, transwell inserts with 8 Wm pore
size were coated with a ¢nal concentration of 0.78 mg/ml of Matrigel.
Cells were trypsinized and 200 Wl of cell suspension (3U105 cells/ml)
per condition were added in triplicate wells. 500 Wl 3T3 conditioned
medium was added to the lower well. After 48 h incubation, the cells
that passed through the ¢lter into the lower wells were quantitated
by MTT assay, and expressed as a percentage of the sum of the cells
in the upper and lower wells [12]. Cells on the lower side of the
membrane were ¢xed, stained with haemalaun and sealed on slides.
Quanti¢cation of invasion through the coated membranes was done
by counting stained cells using a microgrid. Cells were counted
twice by two independent investigators. Inter-observer variation was
below 5%.
2.4. Glioma spheroids
Multicellular glioma spheroids were cultured in 25-cm2 culture
£asks base-coated with 0.75% Noble Agar (Difco Laboratories, De-
troit, MI, USA) prepared in DMEM [13]. Brie£y, 3U106 cells were
suspended in 10 ml medium, seeded onto 0.75% agar plates, and
FEBS 21245 7-12-98
0014-5793/98/$19.00 ß 1998 Federation of European Biochemical Societies. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 9 8 ) 0 1 4 9 4 - X
*Corresponding author. Fax: (49) (7071) 29 6507.
E-mail: michael.weller@uni-tuebingen.de
Abbreviations: ECM, extracellular matrix molecules; MMP, matrix
metalloproteinase; u-PA, cell surface urokinase-type plasminogen
activator; TIMP, tissue inhibitors of metalloproteinases
FEBS 21245 FEBS Letters 440 (1998) 419^424
cultured until spheroids had formed. Spheroids of about 200 Wm
diameter were selected for the experiments.
2.5. Migration assay
The area covered by glioma cells migrating from a tumor spheroid
explanted on a plastic surface was used as an index of cell migration.
Spheroids were transferred individually to 96-well plates (Falcon),
which were uncoated or coated with collagen type IV at 4‡C overnight
at 10 Wg/ml PBS and blocked with 1% BSA containing 200 Wl serum
free medium. Every 24 h for 4 days, the radial distance of migration
was determined after subtraction of the initial spheroid diameter at
time zero from the diameter of the area covered with cells migrated
from the spheroid.
2.6. Fetal rat-brain aggregates
Fetal rat-brain aggregates were obtained from 18-day-old fetuses of
BD9 rats. The brains were aseptically removed and placed into a
sterile tissue-culture plate containing PBS. The brain tissue was
minced, washed in PBS, and dissociated by serial trypsinization. Sin-
gle cell suspensions were obtained and plated into agar-coated 24-well
plates at an average cell amount of one brain per well in 2 ml medium.
After 48 h, aggregates were transferred to new plates and cultured for
19 days. Aggregates with about 200 Wm diameter were used in further
experiments [13].
2.7. Confrontation assays
Invasion of the glioma spheroids into fetal brain aggregates was
analyzed by morphometry using the MCID digitalization system
(IMAGING Research, Ontario, Canada). Brie£y, tumor spheroids
and rat brain aggregates were transferred in triplicate to individual
wells of a 96-well plate, base-coated with agar. With the help of a
sterile syringe and a microscope, tumor spheroids and fetal brain
aggregates were placed in close contact to each other. Images were
obtained at 24-h intervals.
2.8. Cell adhesion assay
Wells of 96-well plates were coated with the individual extracellular
matrix (ECM) proteins at 4‡C overnight at 1^10 Wg/ml PBS and
blocked with 1% BSA. A total of 4U104 cells were added per well
in 100 Wl of DMEM/1% BSA. Cells were allowed to attach for 45 min
at 37‡C in a CO2 incubator. After incubation, plates were gently
washed with Dulbecco’s PBS containing Ca2/Mg2 (DPBS). Adher-
ent cells were ¢xed and stained with 0.2% crystal violet in 10% etha-
nol. Following three washes with PBS, the dye was extracted with 50
mM sodium phosphate, pH 4.5, in 50% ethanol and the absorbance
measured at 540 nm.
2.9. Zymography of MMP-2
Analysis of MMP-2 was performed with sodium dodecyl sulfate-
polyacrylamide gels impregnated with 0.1% gelatin (w/v) and 10%
polyacrylamide (w/v). This assay is based on the digestion of gelatin
and subsequent loss of Coomassie staining at the locus of migration
of gelatinolytic enzymes. Cells were grown in 25-cm2 culture £asks
(Falcon) in DMEM containing 10% FCS until they reached 80%
con£uency. Cells were washed and maintained in serum-free medium,
and the conditioned medium collected after 48 h. Four parts of me-
dium containing equal amounts of protein (50 Wg) from the condi-
tioned medium were mixed with one part of Laemmli sample bu¡er
(minus reductant) [14] prior to electrophoresis. Gels were run at a
constant current and then washed twice for 30 min in 50 mM Tris-
HCl, pH 7.5, plus 2.5% Triton X-100, and then incubated overnight at
37‡C in 50 mM Tris-HCl, pH 7.6, 10 mM CaCl2, 150 mM NaCl,
0.05% NaN3. Gels were stained with Coomassie Brilliant Blue R-
250 and then destained.
2.10. RT-PCR for metalloproteinases, u-PA and TIMPs
The expression of MMP-2, MMP-3, MMP-9, MMP-12, u-PA,
TIMP-1, TIMP-2, and GAPDH was examined by RT-PCR as de-
scribed [18]. For each gene product, ampli¢cation of cDNA was in
the linear range under the cycling conditions.
3. Results and discussion
3.1. BCL-2 gene transfer enhances migration and invasiveness
of LN-18 and LN-229 glioma cells
Polyclonal LN-18 and LN-229 cell lines expressing murine
BCL-2 were generated as described [9]. Endogenous BCL-2
levels were very low in LN-18 cells, and strongly elevated by
BCL-2 gene transfer in both cell lines (Fig. 1A). There was no
signi¢cant di¡erence of doubling times or colony formation
between BCL-2 and neo transfected cell lines (Fig. 1B). The
anti-apoptotic e¡ects of ectopic BCL-2 expression in these
human glioma cell lines have been characterized previously
[9]. To examine whether BCL-2 is involved in glioma cell
migration or invasion, we performed tumor spheroid migra-
tion assays, on plastic or collagen IV, a metalloproteinase-2/-9
proteolysis substrate. BCL-2-transfected LN-18 and LN-229
cells showed signi¢cantly more migratory activity than neo
control cells at 24, 48, 72 and 96 h both in the absence of
coating and in the presence of collagen IV (Fig. 1C) (P6 0.05,
t-test). There was signi¢cantly more migration in LN-229
BCL-2 cells on collagen IV compared with plastic at 24 and
48 h and in LN-18 BCL-2 cells at 72 and 96 h (P6 0.05, t-
test). In principle, these di¡erences in migration could be due
to expression of di¡erent adhesion molecules in the BCL-2-
transfected cells. However, cell adhesion assays excluded that
enhanced migration was due to modi¢cation of cell adhesion
to collagen IV or integrin or non-integrin substrates. We as-
sessed the adhesion of the cell lines to di¡erent substrates:
collagen IV, poly-L-lysine (a non-integrin substrate), and the
integrin substrates, vitronectin and ¢bronectin, in a standard
cell adhesion assay [15]. There was no di¡erence between the
BCL-2-transfected and the neo cells in any of these assays
(data not shown).
The di¡erences in migration on collagen IV could be due to
an up-regulation of collagenases in the BCL-2 cells, thus de-
grading collagen IV and thereby loosening cell-matrix inter-
actions. This could also in£uence the invasive potential of the
glioma cell lines. Therefore, we tested the invasiveness of the
transfected cell lines in Matrigel Boyden chamber assays. In-
terestingly, there was a signi¢cant increase in invasiveness in
the BCL-2 expressing sublines compared with the neo controls
(Fig. 2A). At 48 h, invasion increased from 14 to 36% in LN-
18 and from 33 to 68% in LN-229 cells, as assessed by the
number of cells in the lower wells (Fig. 2B). A similar e¡ect
became apparent when comparing the number of cells adher-
ing to the lower side of the membranes.
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Fig. 1. BCL-2 gene transfer promotes migration of human malignant glioma cells. A: Immunoblot analysis for BCL-2 was performed as de-
scribed in Section 2. B: 103 cells per well were seeded in 96-well plates and growth assessed at 24-h intervals by crystal violet staining (LN-18
neo (open circles), LN-18 BCL-2 (¢lled circles), LN-229 neo (open squares) and LN-229 BCL-2 (¢lled squares); n = 3, S.E.M. 6 10%). Data
are expressed as ratios of optical density units at 570 nm (upper panel). The clonogenicity of LN-18 or LN-229 neo or BCL-2 cells was as-
sessed on six-well plates in 2 ml medium as described in Section 2. Macroscopically visible colonies (0.15 mm) derived from 3U103 cells seeded
per well were quanti¢ed after 17 days (mean S.E.M., n = 3) (lower panel) (Ps 0.05, t-test). C: Tumor cell spheroids derived from LN-18 neo
(open circles), LN-18 BCL-2 (¢lled circles) (LN-18 left side); LN-229 neo (open squares), or LN-229 BCL-2 (¢lled squares) (LN-229 right side)
were prepared and seeded (uncoated well upper panel, collagen IV lower panel) as documented in Section 2. The median distance in Wm from
the center of the spheroid minus the diameter of the spheroid was measured for 50 exemplary, migrated cells (S.E.M. 6 10%). Data are ex-
pressed as mean of three independent experiments performed in triplicate (P6 0.05, t-test).
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3.2. Acceleration of spheroid invasion into rat brain aggregates
by BCL-2
To examine the invasiveness of BCL-2 transfected LN-18
and LN-229 glioma cells in a second paradigm that more
closely resembles the in vivo situation, we co-cultured tumor
spheroids and fetal rat brain aggregates (Fig. 3). Tumor
spheroids from LN-18 and LN-229 BCL-2 cells invaded the
rat brain aggregates signi¢cantly more extensively than neo
control cells. The comparative time course of rat-brain aggre-
gate invasion by neo and BCL-2 cells is depicted in Fig. 3C.
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3.3. Up-regulation of metalloproteinases and u-PA and
down-regulation of TIMP-2 in BCL-2 expressing cells
Since the cells expressing BCL-2 were more invasive in
Matrigel and co-culture assays and since MMP-2 (72-kDa
gelatinase/type IV collagenase = gelatinase A), MMP-3 (stro-
melysin-1), MMP-9 (92-kDa gelatinase/type IV collagenase =
gelatinase B), tissue inhibitors of metalloproteinases 1 and 2
(TIMP-1 and -2) and the cell surface urokinase-type plasmin-
ogen activator (u-PA) may play a vital role in glioma inva-
sion [16], we determined their expression in neo versus BCL-
2 transfected cells. RT-PCR was performed for a representa-
tive set of proteolytic enzymes: MMP-2, MMP-3, MMP-9,
MMP-12, u-PA, TIMP-1, TIMP-2, and for GAPDH as a
reference for equal amounts of cDNA template. There
were prominent di¡erences between LN-18 and LN-229 cells
(Fig. 4A). While LN-18 neo showed strong expression of
MMP-2, MMP-9, u-PA, TIMP-1, and TIMP-2, and a
weak signal for MMP-3, LN-229 neo exhibited no signal
for u-PA and MMP-3. The BCL-2 gene transfer into LN-
18 cells resulted in a substantial up-regulation of MMP-3
and induction of MMP-12 mRNA expresssion, and a minor
up-regulation of MMP-2 mRNA expression. TIMP-1,
TIMP-2 and u-PA mRNA expression were unchanged.
LN-229 BCL-2 glioma cells showed up-regulation of
MMP-9 mRNA expression, whereas MMP-12 and u-PA
were detected only in the transfected cells. The mRNA levels
of MMP-2 were unchanged, as were TIMP-1 levels, but
TIMP-2 mRNA levels were markedly down-regulated in
BCL-2 transfected LN-229 cells. In essence, this might result
in increased MMP-2 activity in the LN-229 BCL-2 cells as
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Fig. 2. BCL-2 gene transfer promotes invasion into Matrigel in LN-18 and LN-229 glioma cells. A: Glioma cells invading through Matrigel-
coated 8-Wm pore size transwell inserts were stained as described in Section 2. B: The number of invading cells was quanti¢ed by counting
stained cells in random ¢elds of the membrane (bars, left axis) or quantifying cells within the lower well by MTT assay (symbols, right axis).
All experiments were performed three times in triplicate and counting was done independently by two investigators. Signi¢cance in both assays
was calculated using the unpaired t-test (*P6 0.05, t-test).
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described by Deryugina et al. [19]. These results are consis-
tent with enhanced invasiveness of both the LN-18 and LN-
229 BCL-2 transfected cells. For LN-18 BCL-2 cells, up-reg-
ulation of MMP-3 and MMP-12 and a moderate increase of
MMP-2 mRNA expression without other signi¢cant changes
seems to represent one pro¢le which promotes migration and
invasiveness. The results for the LN-229 glioma cells are
similar but instead of an increase of MMP-2, MMP-9 is
up-regulated, and TIMP-2 down-regulated. Additionally,
these cells express no MMP-3, but there is an induction of
u-PA expression, the ligand of the u-PA receptor, which is
known to enhance invasion in glioblastoma and shedding of
metastatic cells in prostate cancer [4], in the BCL-2 cells. The
association of de novo MMP-12 expression with a more
motile and invasive phenotype is a novel ¢nding.
3.4. BCL-2-mediated promotion of invasiveness correlates
with increase in MMP-2 activity
Next, we assessed whether BCL-2 promoted changes in
metalloproteinase activity as determined by zymography as-
says. This assay shows the gelatinolytic activity of MMP-2
assessed by degradation of gelatin and maturation of MMP-
2 by detection of cleaved forms. The gelatinolytic pro¢le (Fig.
4B) shows that neo transfected LN-18 and LN-229 cells ex-
press the 68-kDa proform of MMP-2 in conditioned medium.
Both glioma cell lines transfected with BCL-2 express a 62^64-
kDa intermediate product, and the LN-18 BCL-2 cell line also
shows a weak signal of the mature 59-kDa MMP-2 form,
suggesting activation of MMP-2 in the BCL-2-transfected
cells. In this regard, Deryugina et al. [17], studying interac-
tions of TIMP-2, membrane type metalloproteinase-1 (MT1-
MMP) and KvL3 integrin in the activation of MMP-2, postu-
lated that binding of soluble TIMP-2 to MT1-MMP results in
the formation of a catalytic complex to activate pro-MMP-2.
For interaction with the ECM, mature MMP-2 probably must
bind to KvL3 integrin. The authors concluded that MMP-2 of
U251.3 glioma cells is not activated in vitro without exoge-
nous expression of MT1-MMP [17].
In contrast, we observe MMP-2 activation in BCL-2-trans-
fected cells (Fig. 4B), con¢rming and extending our ¢nding of
changes in the expression of MMP-3, MMP-9, MMP-12 and
u-PA (Fig. 4A). To con¢rm the immediate importance of
metalloproteinase activity for migration and invasion, we
tested glioma cell invasion in the Boyden chamber assay or
migration on matrices in the presence of di¡erent proteinase
inhibitors. The inhibitors were directly added to the medium.
Neither aprotinin, a blocker of serine proteinases, nor leupep-
tin, a blocker of cysteine proteinases, nor a combination of
both, had an e¡ect on migration (data not shown) or invasion
(Fig. 4C,D). In contrast, 100 WM O-phenanthroline, a broad
spectrum metalloproteinase inhibitor, strongly blocked migra-
tion (data not shown) and invasion of the LN-18 and LN-229
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Fig. 3. BCL-2 enhances invasiveness of LN-18 and LN-229 glioma cells into fetal rat-brain aggregates. A, B: The experiments were done as
documented in Section 2. The images (A: LN-18 at 0 h and 36 h; B: LN-229 at 0 h and 24 h) show the brain aggregate smaller and the tumor
spheroid relatively larger. C: Invasion was determined using a light microscope and an image analysis system. Invasion was measured as per-
cent of the area of the original rat brain aggregate invaded by tumor cells. Experiments were performed three times in triplicate.
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BCL-2 glioma cells by more than 75% (Fig. 4E). In parallel
experiments, we could inhibit invasion of the neo cell lines in
a similar fashion.
The present study provides evidence for a novel role for
BCL-2 in maintaining a neoplastic phenotype in human glio-
ma cells. Importantly, it remains unclear whether the promo-
tion of migration and invasiveness is completely independent
of the anti-apoptotic properties of BCL-2. The anti-apoptotic
properties of BCL-2 in the same cell lines have previously
been documented by protection from CD95-mediated, drug-
and irradiation-induced apoptosis [9]. The speci¢c changes in
molecules involved in invasion (Fig. 4) lead us to propose that
BCL-2 has speci¢c e¡ects on the molecules relevant for mi-
gration and invasion that warrant further investigation in an
in vivo paradigm and might represent a novel target for can-
cer therapy.
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Fig. 4. Invasive pro¢le of BCL-2 transfected cells correlated with
metalloproteinase activation. A: Semi-quantitative PCR was per-
formed as described in Section 2 [17]. Photographs of the agarose
electrophoreses (LN-18 left panel, LN-229 right panel) are dis-
played. Analysis was performed semi-quantitatively by assessment of
di¡erences of intensity of ethidium bromide-stained bands. B: Gela-
tin zymography of MMP-2 in conditioned medium of neo and
BCL-2 transfected cells was performed as described in Section 2. A
68-kDa band is displayed in LN-229 neo (lane 2), LN-229 BCL-2
(lane 3), LN-18 neo (lane 4), and LN-18 BCL-2 (lane 5) re£ecting
enzyme activity (lane 1 represents a molecular weight marker). C,
D, E: LN-18 BCL-2 cells were examined as in Fig. 2C. The cells
were untreated (C) or exposed to inhibitors of serine (3 WM aproti-
nin) and cysteine (10 WM leupeptin) proteinases (D) or 100 WM
O-phenanthroline (E), a speci¢c metalloproteinase inhibitor.
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